Liquidia Corp (LQDA): Cash & Equivalents
$190.68M
As of 2025-12-31
$284.18M
As of 2026-06-30
+26.9%
3-year compound annual growth
+23.9%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $190.68M | +8.0% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $176.48M | +110.9% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $83.68M | -10.3% | 2025-03-19, Balance as of period end |
| 2022-12-31 | $93.28M | +62.2% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $57.49M | -12.0% | 2023-03-20, Balance as of period end |
| 2020-12-31 | $65.32M | n/a | 2022-03-17, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Liquidia Corp (LQDA) | 2025-12-31 | $190.68M | +8.0% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $28.65M | +11.0% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $57.22M | -68.7% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | $60.54M | -3.1% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $134.93M | -12.4% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $129.97M | -56.3% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $250.49M | +633.8% |
| Lifevantage Corp (LFVN) | 2025-06-30 | $20.20M | +19.6% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $84.22M | -34.2% |
Compare LQDA, HRTX, MGNX, KPTI side by side · Screen every company in Pharmaceutical Preparations ↗